BETA-TESTING OF NEW HEALTHTAB™ SYSTEM IN FIRST SHOPPERS DRUG MART® PHARMACY PERFORMS WELL, SHOWS STRONG PATIENT DEMAND

 

VANCOUVER, BRITISH COLUMBIA – July 19, 2021 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company”; or “AVCR”) announces that patient testing has begun on the first deployment of the newHealthTab™-integrated Afinion 2™ analyzers in the initial Shoppers Drug Mart® pharmacy location as part of its previously announced effort to screen for diabetes and cardiovascular disease, demonstrating strong demand, smooth workflow, and reliable system operations.


To prepare for the full public launch of the program, announced in May of this year, a first store was
selected to receive the system to begin beta-testing HealthTab™’s systems, including the first patient
tests. This work has successfully demonstrated that the very first installation of HealthTab™ with the
Afinion 2™ analyzers is ready for prime-time, with HealthTab™ and the instruments performing well.
So successful was the initial week that more than 90 patients were tested and over 600 results were
reported over the initial trial period between July 5 – July 18 at this single location.


“I’m so excited to have HealthTab™ in my store because I believe this is going to demonstrate a new and
better way to do pharmacy practice,” said Mohamed Adel Elsabakhawi, the first Pharmacist and
Associate Owner of a Shoppers Drug Mart located in Mississauga, Ontario to operate the platform. “This
is really profound because having access to lab-accurate results at our fingertips means we can better
help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and
cardiovascular patients more effectively.”


In May 2021, HealthTab™ signed a Master Agreement with Shoppers Drug Mart Inc. to pilot the
HealthTab™ platform. This agreement allows patients access to point-of-care blood screening and
health-data management for potential risks for developing diabetes and cardiovascular conditions through
the HealthTab™-integrated Afinion 2™ analyzers by Abbott Rapid Diagnostics.


All locations have now received their HealthTab™ systems and are being prepared to be online as soon.
To find a location near you, please visit: healthtab.com/locations

 

About HealthTab™ + RASTR

 

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab  test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.  Results can be printed in-store or accessed securely online.

 

As part of this direction for HealthTab™ the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

 

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities.  This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector. 

 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

 

And, with the emergence of COVID-19 and its variants, the HealthTab™ + RASTR platform can now directly report results from the Abbott ID Now™, or manually report results from rapid-tests, dramatically reducing the administration time and increasing the accuracy and speed of information sharing. 

 

About Avricore Health Inc.

 

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Contact:

 

Avricore Health Inc.

Hector Bremner, CEO 604-773-8943               
info@avricorehealth.com 

www.avricorehealth.com 

 

Cautionary Note Regarding Forward-Looking Statements 

Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. 

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this statement.